Marc J. Fishman, M.D.

Marc J. Fishman, M.D.
Marc J. Fishman, M.D.
Affiliated Senior Research Scientist

M.D., Columbia College of Physicians and Surgeons
mjfishman@comcast.net
Phone: 410-233-1400
Research Interests

Dr. Fishman is board certified in addiction psychiatry and addiction medicine. He is a member of the Psychiatry faculty of the Johns Hopkins University School of Medicine, and Medical Director of Maryland Treatment Centers.

Dr Fishman leads Maryland Treatment Centers, a regional behavioral health care provider, which includes Mountain Manor Treatment Center in Baltimore for adolescents, Mountain Manor Treatment Center in Emmitsburg MD for adults, as well as several other inpatient and outpatient programs. In that role he has been involved in development and implementation of innovative programming in addiction and co-occurring disorder treatment. His clinical specialties include treatment of drug-involved and dual-diagnosis adolescents, opioid dependence in adolescents and adults, and addiction with co-morbid pain. His research work has focused on models of care and treatment outcomes in adolescent addictions, in particular opioid dependence.

Dr. Fishman served as a co-editor for the most recent edition of ASAM’s Patient Placement Criteria (PPC 2-R), and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Treatment Criteria Committee for ASAM. He is the President (2010-12) of the Maryland Society of Addiction Medicine.

Selected Publications
Nunes EV, Gordon MS, Friedmann PD, Fishman MJ, Lee JD, Chen DT, Hi MC, Boney TB, Wilson D, O’Brien CP (2018). Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. Journal of Substance Abuse Treatment.
Lee JD, Friedmann PD, Boney TY, Hoskinson RA Jr, McDonald R, Gordon MS, Fishman M, Chen DT, Bonnie RJ, Kinlock TW, Nunes EV, Cornish JW, O’Brien CP (2015). Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. Contemporary Clinical Trials. 41:110-7.
Branson C, Clemmey P, Harrell P, Subramaniam G, Fishman M (2012). Polysubstance use and heroin relapse among adolescents following residential treatment. Journal of Child and Adolescent Substance Abuse. 21(3).
Warden D, Subramaniam GA, Carmody T, Woody GE, Minhajuddin A, Poole SA, Potter J, Fishman M, Bogenschutz M, Patkar A, Trivedi MH (2012). Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addictive Behaviors. 37(9):1046-53.
Winstanley E, Steinwachs D, Stitzer M, Fishman M (2012). Adolescent substance abuse and mental health: Problem co-occurrence and access to services. Journal of Child and Adolescent Substance Abuse. 21(4): 310-22.
Fishman M J, Wu LT, and Woody G (2011). Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence. American Journal of Psychiatry. 168(7).
Subramaniam G, Warden D, Minhajuddin A, Fishman M, Stitzer M, Adinoff B, Trivedi M, Weiss R, Potter J, Poole S, Woody GE (2011). Predictors of abstinence: NIDA multi-site buprenorphine/naloxone treatment trial in opioid dependent youth. Journal of the American Academy of Child and Adolescent Psychiatry. 50(11):1120-8.
Fishman M (2010). Treatment planning, matching and placement for adolescent substance abuse. In: Kaminer Y, Winters K, eds. Clinical Manual of Adolescent Substance Abuse Treatment. American Psychiatric Publishing.
Fishman M (Chief Editor), Shulman J, Mee-Lee D, Kolodner G, Wilford B, eds (2010). ASAM patient placement criteria supplement on pharmacotherapy for alcohol use disorders. Lippincott Williams and Wilkens.
Fishman M, Winstanley E, Curran E, Garrett S, Subramaniam G (2010). Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case series and feasibility. Addiction. 105: 1669-1676.
Winstanley E, Bolon S, Fishman M (2010). Treatment outcomes for addictive disorders in Addictive Disorders in Medical Populations, Miller N and Gold M (eds). John Wiley & Sons, Ltd.
Subramaniam G, Fishman M, Woody G (2009). Treatment of opioid-dependent adolescents and young adults with buprenorphine. Current Psychiatry Reports. 11:360–3.
Subramaniam G, Stitzer M, Woody G, Fishman M, Kolodner K (2009). Clinical characteristics of treatment seeking adolescents with opioid versus cannabis/alcohol use disorders. Drug and Alcohol Dependence. 99:141 49.
Subramaniam G, Stitzer M, Clemmey P, Kolodner K, Fishman M (2007). Baseline Depressive Symptoms Predict Poor Substance Use Outcome Following Adolescent Residential Treatment. Journal of the American Academy of Child and Adolescent Psychiatry. 46(8): 1062-9.
Mee-Lee D, Shulman GD, Fishman M, Gastfriend D, eds (2001). ASAM Patient Placement Criteria for the Treatment of Substance-Related Disorders, Second Edition-Revised (ASAM PPC-2R). American Society of Addiction Medicine, Inc.